Statement of Investor Grievances under Regulation 13(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.
Statement Of Investor Grievances Under Regulation 13(3) Of SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015.
Filed with BSE ·
6ix hasn’t read this filing yet.
View original source (BSE India)Welcure Drugs and Pharmaceuticals Ltd. on 6ix
Earlier from Welcure Drugs and Pharmaceuticals
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Dec 27 2024
- Closure of Trading Window
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Dec 04 2024
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Later from Welcure Drugs and Pharmaceuticals
- Submission Of SDD Compliance Certificate Under Regulation 3(5) And 3(6) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 For The Quarter Ended December 31St, 2024.
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Jan 21 2025
- Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Wednesday, 22Nd January, 2025
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Jan 22 2025
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Follow Welcure Drugs and Pharmaceuticals into a list and get an email when it puts out news.
Follow Welcure Drugs and Pharmaceuticals